REAL-WORLD COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN SYMPTOMATIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PORTUGAL

被引：0
|
作者：
Afonso-Silva, M. [1 ]
Laires, P. A. [1 ]
机构：
[1] Prod Farmaceut SA, Novartis Farma, Porto Salvo, Portugal
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV24
引用
收藏
页码：S545 / S545
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN FOR THE TREATMENT OF SYMPTOMATIC CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PORTUGAL
    Alarcao, J.
    Ascencao, R.
    Costa, J.
    Gouveia, M.
    Borges, M.
    [J]. VALUE IN HEALTH, 2018, 21 : S104 - S104
  • [2] Cost-effectiveness of sacubitril/valsartan for the treatment of patients with heart failure with reduced ejection fraction in Portugal
    Borges, Margarida
    Afonso-Silva, Marta
    Laires, Pedro A.
    Gouveia, Miguel
    Alarcao, Joana
    Ascencao, Raquel
    Costa, Joao
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2020, 20 (02) : 199 - 205
  • [3] COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN HEART FAILURE WITH REDUCED EJECTION FRACTION IN SWEDEN
    Costa-Scharplatz, M.
    Lang, A.
    McMurray, J. J.
    Woodcock, F.
    Haroun, R.
    Johansson, D.
    Lund, L. H.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A650 - A651
  • [4] Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction
    McMurray, John J. V.
    Trueman, David
    Hancock, Elizabeth
    Cowie, Martin R.
    Briggs, Andrew
    Taylor, Matthew
    Mumby-Croft, Juliet
    Woodcock, Fionn
    Lacey, Michael
    Haroun, Rola
    Deschaseaux, Celine
    [J]. HEART, 2018, 104 (12) : 1006 - 1013
  • [5] The cost-effectiveness of sacubitril/valsartan in chronic heart failure with reduced ejection fraction
    Mcmurray, J. J. V.
    Cowie, M. R.
    Briggs, A.
    Taylor, M.
    Hancock, E.
    Trueman, D. David
    Haroun, R.
    Deschaseaux, C.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 : 276 - 276
  • [6] Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction
    Sandhu, Alexander T.
    Ollendorf, Daniel A.
    Chapman, Richard H.
    Pearson, Steven D.
    Heidenreich, Paul A.
    [J]. ANNALS OF INTERNAL MEDICINE, 2016, 165 (10) : 681 - +
  • [7] COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION IN SINGAPORE
    Declan, L.
    Tang, Z. X.
    Ng, C.
    Tan, J.
    Trueman, D.
    Woodcock, F.
    Cristino, J.
    [J]. VALUE IN HEALTH, 2018, 21 : S106 - S106
  • [8] Cost-effectiveness of Sacubitril/Valsartan in acute and chronic heart failure with reduced ejection fraction: From randomized controlled trials to real-world evidence
    Lin, Y. M.
    Yang, C. T.
    Kuo, F. S.
    Toh, H. S.
    Yang, I. N.
    Hung, C. Y.
    Liao, C. T.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 305 - 305
  • [9] COST-EFFECTIVENESS OF DAPAGLIFLOZIN VERSUS SACUBITRIL/VALSARTAN FOR THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION
    McEwan, P.
    Darlington, O.
    Bergenheim, K.
    Qin, L.
    [J]. VALUE IN HEALTH, 2020, 23 : S494 - S494
  • [10] THE COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN TURKEY
    Sarioz, F.
    Ozdemir, O.
    Direk, S.
    Caglar, P.
    Ar, I
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A616 - A616
12345